| III-51 Amina Bensalem The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition |
| III-51 Amina Bensalem The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition |